Colin Broom, BSc, MB BS, MRCP, FFPM
Dr. Broom has been our CEO since September 2019. Over the past 30 years he has been involved in all stages of drug development and commercialization across multiple therapeutic areas including oncology, anti-infectives and pulmonary medicine. He served as CEO of Nabriva Therapeutics plc until July 2018 and remains a member of the Board of Directors. Previously he was Chief Scientific Officer at ViroPharma Inc. until its acquisition by Shire in 2014 and was a member of the Board of NPS Pharmaceuticals. Previous positions include a range of international leadership roles with Amgen, SmithKline Beecham and Glaxo (now Glaxo SmithKline). He has a BSc in Pharmacology from University College, London and received his medical degree and clinical training at St George’s Hospital Medical School in London. He is a member of the Royal College of Physicians of the UK and a fellow of the Faculty of Pharmaceutical Medicine.
BRENTON SCOTT, PHD
President and Chief Operating Officer
Dr. Scott is a co-founder of the company and has helped lead the initial technology out of the lab and into the clinic. Prior to his industry role, his academic experience focused on vesicular traffic, airway inflammation and infection. He serves as the PI on multiple grant awards, including the Cancer Prevention Research Institute of Texas (CPRIT) and Texas Emerging Technology Fund (TETF) awards from the State of Texas and seven Small Business Innovative Research (SBIR) awards. He is a regular reviewer of SBIR grant applications for the NIH. He concurrently received his PhD in Biochemistry and Cell Biology from Rice University and his MBA from University of Houston.
William J. Noss, CPA, CGMA
Chief Financial Officer
Mr. Noss has been our CFO since June 2021. He joins Pulmotect with over 15 years of experience in the life science industry in varying stages of development and commercialization. Prior to Pulmotect, Mr. Noss was Executive Director / Controller for Harmony Biosciences, where he helped lead the company through their commercial launch and subsequently through their initial public offering of $148M. Before Harmony, he was Head of Finance at Aevi Genomic Medicine. Mr. Noss’s previous experience also includes various roles with Telerx, ViroPharma Incorporated, and KPMG LLP. Mr. Noss holds a Bachelor of Science in Accounting from King’s College, is a Chartered Global Management Accountant and a Certified Public Accountant.
JOHN SCHAUMBERG, PhD
Head, Clinical Operations
Dr. Schaumberg has more than 30 years of drug development expertise, including experience with global pharmaceutical organizations, biotechnology companies and clinical research organizations. His past roles include Vice President level positions in Biotech as Senior Vice President, Clinical Operations of Agennix AG as well as Vice President level positions in the clinical research organizations PRA International and Inveresk. Prior to Inveresk, he held a variety of clinical development and project management roles with Glaxo, Parke-Davis and Valentis. While at Glaxo, he was involved in the clinical development programs of Serevent®, a long acting beta agonist, and Flovent®, an inhaled corticosteroid, for the treatment of asthma. Dr. Schaumberg received his Ph.D. from the University of Iowa (U.S.) in Medicinal Chemistry and Natural Products, and his Bachelor of Pharmacy from Washington State University (U.S.).
Anoshie Ratnayake, MD
Dr. Ratnayake brings over 12 years of leadership experience in clinical research and drug development. She has provided strategic guidance for early phase drug development, including for several novel pulmonary, allergy, asthma, and immunomodulating drugs. She received her bachelor’s degree (BA) from Stanford University, MD from University of Southern California (USC) Keck School of Medicine, and MPH from Harvard University. She completed postgraduate training at University of Texas Southwestern Medical Center, allergy/Immunology fellowship training at USC, and practiced as an allergist and immunologist for over 9 years.
Rena Johnson, PHD
Dr. Rena Johnson is a Project Manager at Pulmotect. She joined the company in May 2018. Dr. Johnson received her Ph.D. in Biology from the University of Kiel, Germany in 2011. She moved to the US for a postdoctoral training at the Center for Lung Biology at the University of Washington, Seattle and at the Women’s Guild Lung Institute at Cedars-Sinai Medical Center, Los Angeles with Dr. Peter Chen. During her postdoctoral training, her research focused on the role of the lung epithelium in acute lung injury, especially in the response to influenza infection with particular interest in the role of syndecan-1, the major proteoglycan expressed by epithelial cells in the lung. She has strong interest in translating innovation from the lab bench to novel bio-medical solutions that can ultimately improve patient’s health.